Covexin 10
Active substance
ATC code
Species
Sheep and cattle.
Indications
For the active immunisation of sheep and cattle against diseases associated with infections caused by Clostridium perfringens type A, C. perfringens type B, C. perfringens type C, C. perfringens type D, Clostridium chauvoei, Clostridium novyi type B, Clostridium septicum, Clostridium sordellii and Clostridium haemolyticum and against tetanus caused by Clostridium tetani.
For the passive immunisation of lambs and calves against infections caused by the above mentioned clostridial species (except C. haemolyticum in sheep).
Onset of immunity: 2 weeks after the basic vaccination course (as demonstrated by serology only).
Duration of active immunity as demonstrated by serology only:
Sheep: 12 months against C. perfringens type A, B, C and D, C. novyi type B, C. sordellii, C. tetani
< 6 months against C. septicum, C. haemolyticum, C. chauvoei
Cattle: 12 months against C. tetani and C. perfringens type D
< 12 months against C. perfringens type A, B and C
< 6 months against C. novyi type B, C. septicum, C. sordellii, C. haemolyticum, C. chauvoei
Additionally, an anamnestic humoral immune response (immunological memory) to all components was demonstrated after antigen stimulation 12 months after the basic vaccination course.
Duration of passive immunity as demonstrated by serology only:
Lambs:
At least 2 weeks for C. septicum and C. chauvoei, at least 8 weeks for C. perfringens type B and C. perfringens type C and at least 12 weeks for C. perfringens type A, C. perfringens type D, C. novyi type B, C. tetani and C. sordellii. No passive immunity was observed for C. haemolyticum.
Calves:
At least 2 weeks for C. sordellii, and C. haemolyticum, at least 8 weeks for C. septicum and C. chauvoei and at least 12 weeks for C. perfringens type A, C.
perfringens type B, C. perfringens type C, C. perfringens type D, C. novyi type B, and C. tetani.
Dose to be administered and administration route
Sheep – from 2 weeks of age: Dose - 1 ml.
Cattle – from 2 weeks of age: Dose – 2 ml.
Administration:
By subcutaneous injection at a suitable site. The recommended site is the loose skin on the side of the neck.
The bottle should be well shaken before any vaccine is withdrawn.
Syringes and needles should be sterile before use and the injection should be made through an area of clean, dry skin taking precautions against contamination.
Basic vaccination scheme:
Two doses should be administered, 4-6 weeks apart (see section 4.2 and 4.4).
Re-vaccination scheme:
A single dose should be administered every 6 to 12 months after the basic vaccination scheme (see also point 4.2).
Use in pregnancy:
To provide passive protection of the offspring, via the colostrum, a single booster dose should be administered between 8 and 2 weeks before parturition, provided that animals have received a full basic vaccination course before pregnancy.
Adverse reactions
In the event of an anaphylactic reaction appropriate treatment such as adrenaline should be administered without delay.
Very commonly, animals vaccinated with Covexin 10 may experience reactions to vaccination. These reactions are usually localised swelling, induration or other reaction in the underlying tissue at the injection site (very commonly) but may also include mild hyperthermia (very commonly).
Swelling at the injection site occurs very commonly. This swelling may reach up to a mean value of 6 cm in diameter in sheep and 15 cm in diameter in cattle; though some cattle reactions of up to 25 cm in diameter may be observed. Most local reactions resolve within 3-6 weeks in sheep and in less than 10 weeks in cattle but may persist longer. Commonly, an abscess may develop in some animals.
Skin discolouration at the injection site (which returns to normal as the local reaction resolves) may commonly occur. Localised pain at the injection site for 1-2 days post first vaccination may occur commonly.
The local reactions do not affect the general health, demeanour, feeding or weight gain of the animals.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
